

Anait L Melikyan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3410239/anait-l-melikyan-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20

papers

38

citations

4

h-index

6

g-index

21

ext. papers

49

ext. citations

0.8

avg, IF

1.01

L-index

#	Paper	IF	Citations
20	Analysis of T-cell receptor-gamma gene rearrangements using oligonucleotide microchip: a novel approach for the determination of T-cell clonality. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 249-57	5.1	9
19	Biology of Myeloproliferative Malignancies. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2016, 9, 314-325	0.3	7
18	National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2020). <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 262-298	0.3	7
17	Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease. <i>Cerebrovascular Diseases Extra</i> , 2016, 6, 66-70	2.1	6
16	Human Herpesvirus Type 8-positive Multicentric Castleman Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16 Suppl, S159-65	2	3
15	INTERIM RESULTS OF EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS IN THE RUSSIAN FEDERATION: INTERMEDIATE RESULTS. <i>Gematologiya I Transfuziologiya</i> , 2019, 64, 436-446	0.4	2
14	Current View on Diagnosis and Treatment of Classical Ph-Negative Myeloproliferative Neoplasms. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 129-137	0.3	2
13	Treatment of Portal Thrombosis in Patients with Myeloproliferative Neoplasms: A Single-Institution Experience. <i>Blood</i> , 2014, 124, 5098-5098	2.2	1
12	Dermatological Toxicity of Hydroxycarbamide. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2018, 11, 252-258	0.3	1
11	Current Issues of Targeted Therapy of Polycythemia Vera. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 355-360	0.3	0
10	National clinical recommendations for the diagnosis and treatment of mastocytosis. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 280-311	0.4	0
9	Frequency of coexistence and kinetics of the BCR-ABL1 transcript level and allele burden of JAK2V617F and CALR Type 1, 2 gene mutations in patients with chronic myeloid leukemia. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 253-280	0.4	
8	Kaposi's sarcoma in HIV-negative patient with primary myelofibrosis. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 433-444	0.4	
7	Efficacy of splenectomy in primary immune thrombocytopenia. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 362-373	0.4	
6	Cerebrovascular Disorders Associated with Ph-Negative Myeloproliferative Diseases. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2019, 12, 398-405	0.3	
5	Comparative characteristics of bone marrow cell composition, stroma, and trabecular bone in allogenic hematopoietic stem cell transplantation in patients with primary myelofibrosis. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 68-78	0.4	
4	Thrombosis in patients with myeloproliferative neoplasms. Case report. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 800-804	0.9	

- 3 Cephalgia against the background of systemic mastocytosis: a clinical case. *Bulletin of Siberian Medicine*, **2021**, 20, 239-244 0.4
- 2 Repeated haploidentical allogeneic hematopoietic stem cell transplantation with TCR β CD19 depletion in patient with primary myelofibrosis. Case report. *Terapevticheskii Arkhiv*, **2021**, 93, 805-810 0.9
- 1 Correlation of the Number of TGF β 1-Expressing Atypical Megakaryocytes with the Degree of Bone Marrow Stroma Fibrosis and Osteosclerosis in Patients with Essential Thrombocythemia and Different Stages of Primary Myelofibrosis. *Klinicheskaya Onkogematologiya/Clinical Oncohematology*, **2022**, 15, 76-84 0.3